BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 27791010)

  • 1. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.
    Zhao S; Bellone S; Lopez S; Thakral D; Schwab C; English DP; Black J; Cocco E; Choi J; Zammataro L; Predolini F; Bonazzoli E; Bi M; Buza N; Hui P; Wong S; Abu-Khalaf M; Ravaggi A; Bignotti E; Bandiera E; Romani C; Todeschini P; Tassi R; Zanotti L; Odicino F; Pecorelli S; Donzelli C; Ardighieri L; Facchetti F; Falchetti M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Mane S; Angioli R; Terranova C; Quick CM; Edraki B; Bilgüvar K; Lee M; Choi M; Stiegler AL; Boggon TJ; Schlessinger J; Lifton RP; Santin AD
    Proc Natl Acad Sci U S A; 2016 Oct; 113(43):12238-12243. PubMed ID: 27791010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.
    Le Gallo M; Rudd ML; Urick ME; Hansen NF; ; Merino MJ; Mutch DG; Goodfellow PJ; Mullikin JC; Bell DW
    Cancer; 2018 Jan; 124(1):65-73. PubMed ID: 28940304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational and Immunophenotypic Profiling of a Series of 8 Tubo-ovarian Carcinosarcomas Revealed a Monoclonal Origin of the Disease.
    Trento M; Munari G; Carraro V; Lanza C; Salmaso R; Pizzi S; Santoro L; Chiarelli S; Dal Santo L; Nardelli GB; Saccardi C; Nicoletto O; Baldoni A; Rugge M; Fassan M
    Int J Gynecol Pathol; 2020 Jul; 39(4):305-312. PubMed ID: 31688243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing inter-component heterogeneity of biphasic uterine carcinosarcomas.
    Liu Y; Weber Z; San Lucas FA; Deshpande A; Jakubek YA; Sulaiman R; Fagerness M; Flier N; Sulaiman J; Davis CM; Fowler J; Starks D; Rojas-Espaillat L; Lazar AJ; Davies GE; Ehli EA; Scheet P
    Gynecol Oncol; 2018 Nov; 151(2):243-249. PubMed ID: 30194005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated Molecular Characterization of Uterine Carcinosarcoma.
    Cherniack AD; Shen H; Walter V; Stewart C; Murray BA; Bowlby R; Hu X; Ling S; Soslow RA; Broaddus RR; Zuna RE; Robertson G; Laird PW; Kucherlapati R; Mills GB; ; Weinstein JN; Zhang J; Akbani R; Levine DA
    Cancer Cell; 2017 Mar; 31(3):411-423. PubMed ID: 28292439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas.
    Moukarzel LA; Ferrando L; Da Cruz Paula A; Brown DN; Geyer FC; Pareja F; Piscuoglio S; Papanastasiou AD; Fusco N; Marchiò C; Abu-Rustum NR; Murali R; Brogi E; Wen HY; Norton L; Soslow RA; Vincent-Salomon A; Reis-Filho JS; Weigelt B
    Mol Oncol; 2021 Apr; 15(4):1024-1039. PubMed ID: 33021035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular genetic aberrations of ovarian and uterine carcinosarcomas--a CGH and FISH study.
    Schipf A; Mayr D; Kirchner T; Diebold J
    Virchows Arch; 2008 Mar; 452(3):259-68. PubMed ID: 18193277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition.
    Cuevas IC; Sahoo SS; Kumar A; Zhang H; Westcott J; Aguilar M; Cortez JD; Sullivan SA; Xing C; Hayes DN; Brekken RA; Bae-Jump VL; Castrillon DH
    Proc Natl Acad Sci U S A; 2019 Dec; 116(51):25880-25890. PubMed ID: 31772025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors.
    Wada H; Enomoto T; Fujita M; Yoshino K; Nakashima R; Kurachi H; Haba T; Wakasa K; Shroyer KR; Tsujimoto M; Hongyo T; Nomura T; Murata Y
    Cancer Res; 1997 Dec; 57(23):5379-85. PubMed ID: 9393763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin.
    Growdon WB; Roussel BN; Scialabba VL; Foster R; Dias-Santagata D; Iafrate AJ; Ellisen LW; Tambouret RH; Rueda BR; Borger DR
    Gynecol Oncol; 2011 Apr; 121(1):212-7. PubMed ID: 21168197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Carcinosarcomas of the uterus: molecular-genetic and morphological features].
    Levitskaia NV; Pozharisskiĭ KM; Vostriukhina OA; Alekseeva LN; Nemtsova MV; Matrosova IV; Kharitonova TV; Poddubnaia IV
    Arkh Patol; 2012; 74(1):7-11. PubMed ID: 22712296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression profiles of carcinosarcoma of the uterine corpus-are these similar to carcinoma or sarcoma?
    Chiyoda T; Tsuda H; Tanaka H; Kataoka F; Nomura H; Nishimura S; Takano M; Susumu N; Saya H; Aoki D
    Genes Chromosomes Cancer; 2012 Mar; 51(3):229-39. PubMed ID: 22072501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel targeted therapies in ovarian and uterine carcinosarcomas.
    Han C; Altwerger G; Menderes G; Haines K; Feinberg J; Lopez S; Manzano A; Varughese J; Santin AD
    Discov Med; 2018 Jun; 25(140):309-319. PubMed ID: 30021104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.
    Kuhn E; Wu RC; Guan B; Wu G; Zhang J; Wang Y; Song L; Yuan X; Wei L; Roden RB; Kuo KT; Nakayama K; Clarke B; Shaw P; Olvera N; Kurman RJ; Levine DA; Wang TL; Shih IeM
    J Natl Cancer Inst; 2012 Oct; 104(19):1503-13. PubMed ID: 22923510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional role of ALK-related signal cascades on modulation of epithelial-mesenchymal transition and apoptosis in uterine carcinosarcoma.
    Inoue H; Hashimura M; Akiya M; Chiba R; Saegusa M
    Mol Cancer; 2017 Feb; 16(1):37. PubMed ID: 28193280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compartment-specific multiomic profiling identifies SRC and GNAS as candidate drivers of epithelial-to-mesenchymal transition in ovarian carcinosarcoma.
    Herrington CS; Oswald AJ; Stillie LJ; Croy I; Churchman M; Hollis RL
    Br J Cancer; 2024 Feb; 130(2):327-335. PubMed ID: 38097740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus: clinicoimmunohistochemical and histogenetic characteristics.
    Kedzia W; Pruski D; Iwaniec K; Przybylski M; Friebe Z; Rajpert-Kedzia H
    Folia Histochem Cytobiol; 2012; 50(4):513-8. PubMed ID: 23264213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of epithelial-mesenchymal transition factors in the histogenesis of uterine carcinomas.
    Franceschi T; Durieux E; Morel AP; de Saint Hilaire P; Ray-Coquard I; Puisieux A; Devouassoux-Shisheboran M
    Virchows Arch; 2019 Jul; 475(1):85-94. PubMed ID: 30739164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PPP2R1A mutations are common in the serous type of endometrial cancer.
    Nagendra DC; Burke J; Maxwell GL; Risinger JI
    Mol Carcinog; 2012 Oct; 51(10):826-31. PubMed ID: 21882256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HDAC Inhibition Induces Cell Cycle Arrest and Mesenchymal-Epithelial Transition in a Novel Pleural-Effusion Derived Uterine Carcinosarcoma Cell Line.
    Stockhammer P; Okumus Ö; Hegedus L; Rittler D; Ploenes T; Herold T; Kalbourtzis S; Bankfalvi A; Sucker A; Kimmig R; Aigner C; Hegedus B
    Pathol Oncol Res; 2021; 27():636088. PubMed ID: 34257602
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.